SCHEMBL16618006

SCHEMBL16618006

CC1(C(=O)O)CCCCC1c1oc(-c2cccc(Cl)c2)nc1-c1ccc(Br)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.38
PTGFR P43088 1/20 0.37
IKBKB O14920 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
AHR P35869 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CNR2 P34972 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
TP53 P04637 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
GRM5 P41594 3/20 0.34
GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16618003 1.00 KDR (0.38) KDRPTGFRIKBKBNPC1RAB9A
SCHEMBL16617381 0.79 IKBKB (0.39) KDRIKBKBNPC1RAB9AL3MBTL1
SCHEMBL16616900 0.79 IKBKB (0.39) KDRIKBKBNPC1RAB9AL3MBTL1
SCHEMBL16618005 0.76 SLC6A2 (0.43) KDRIKBKBNPC1RAB9ASMN1; SMN2
SCHEMBL16638002 0.76 SLC6A2 (0.43) KDRIKBKBNPC1RAB9ASMN1; SMN2
SCHEMBL16617398 0.72 CTSK (0.57) CNR2MEN1KMT2A
SCHEMBL16638025 0.66 CTSK (0.40)
SCHEMBL16618010 0.66 CTSK (0.40)
SCHEMBL16617824 0.66 CTSK (0.40)
SCHEMBL18003670 0.64 IKBKB (0.51) IKBKBNPC1RAB9AKDM4EUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055314-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2018-09-12 EP disclosed
US-9458181-B2 Cathepsin cysteine protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-10-04 US disclosed
EP-3055314-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054089-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099719-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS CTSB, CTSS, CTSZ KDR 4645/4885PTGFR 2212/4885IKBKB 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.